Isoray (NYSEAMERICAN:ISR) Posts Quarterly Earnings Results, Meets Expectations

Isoray (NYSEAMERICAN:ISR) issued its quarterly earnings data on Monday. The healthcare company reported ($0.01) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.01), MarketWatch Earnings reports. Isoray had a negative return on equity of 15.33% and a negative net margin of 36.52%. During the same period in the prior year, the company earned ($0.02) EPS.

Shares of NYSEAMERICAN:ISR opened at $0.65 on Wednesday. The firm has a market capitalization of $91.95 million, a price-to-earnings ratio of -13.00 and a beta of 1.02. The stock’s 50-day moving average price is $0.45. Isoray has a 12 month low of $0.35 and a 12 month high of $2.81.

ISR has been the subject of several analyst reports. Zacks Investment Research upgraded Isoray from a “sell” rating to a “hold” rating in a research note on Thursday, July 15th. Northland Securities initiated coverage on Isoray in a research note on Tuesday, September 14th. They issued an “outperform” rating and a $1.25 target price for the company. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $1.67.

A hedge fund recently raised its stake in Isoray stock. Morgan Stanley increased its stake in Isoray, Inc. (NYSEAMERICAN:ISR) by 3,364.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 76,224 shares of the healthcare company’s stock after buying an additional 74,024 shares during the quarter. Morgan Stanley owned about 0.05% of Isoray worth $61,000 as of its most recent filing with the SEC. Institutional investors own 12.46% of the company’s stock.

About Isoray

IsoRay, Inc is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors.

See Also: What are the Benefits of Index Funds?

Earnings History for Isoray (NYSEAMERICAN:ISR)

Receive News & Ratings for Isoray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isoray and related companies with MarketBeat.com's FREE daily email newsletter.